This topic directly connects with our course objective by describing the full digestive process and what happens when a step, specifically involving the stomach, is disrupted
Short-acting GLP-1 RAs, exenatide and lixisenatide, are associated with a transient (112 h) mean placebo- and baseline-adjusted 24-h HR increase of 13 beats per minute (bpm)
Register for our upcoming webinar, Expanding Access to Obesity Care , for a practical discussion on evolving benefit strategies and sustainable approaches employers can use today
How to Check if a Plan Covers GLP-1 Medications While some patients may struggle to get GLP-1 drugs covered, you shouldn't assume the worst
doi: 10.1002/cbdv.202301507
Cardiovascular disease As a precaution, patients with active cardiovascular conditions should discuss the risk-benefit profile with their provider before starting PT-141